214 related articles for article (PubMed ID: 19806487)
1. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study.
Small W; Wood E; Betteridge G; Montaner J; Kerr T
AIDS Care; 2009 Jun; 21(6):708-14. PubMed ID: 19806487
[TBL] [Abstract][Full Text] [Related]
2. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
3. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
4. Determinants of HAART discontinuation among injection drug users.
Kerr T; Marshall A; Walsh J; Palepu A; Tyndall M; Montaner J; Hogg R; Wood E
AIDS Care; 2005 Jul; 17(5):539-49. PubMed ID: 16036240
[TBL] [Abstract][Full Text] [Related]
5. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
6. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
8. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
9. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women.
Kapadia F; Vlahov D; Wu Y; Cohen MH; Greenblatt RM; Howard AA; Cook JA; Goparaju L; Golub E; Richardson J; Wilson TE
Am J Drug Alcohol Abuse; 2008; 34(2):161-70. PubMed ID: 18293232
[TBL] [Abstract][Full Text] [Related]
10. HIV risks associated with incarceration among injection drug users: implications for prison-based public health strategies.
Werb D; Kerr T; Small W; Li K; Montaner J; Wood E
J Public Health (Oxf); 2008 Jun; 30(2):126-32. PubMed ID: 18387974
[TBL] [Abstract][Full Text] [Related]
11. Validity of self-reported adherence among injection drug users.
Kerr T; Hogg RS; Yip B; Tyndall MW; Montaner J; Wood E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):157-9. PubMed ID: 18626123
[TBL] [Abstract][Full Text] [Related]
12. Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women.
Cruess DG; Minor S; Antoni MH; Millon T
J Pers Assess; 2007 Dec; 89(3):277-90. PubMed ID: 18001228
[TBL] [Abstract][Full Text] [Related]
13. The opinions of injecting drug user (IDUs) HIV patients and health professionals on access to antiretroviral treatment and health services in Valencia, Spain.
Garcia de la Hera M; Davo MC; Ballester-Añón R; Vioque J
Eval Health Prof; 2011 Sep; 34(3):349-61. PubMed ID: 21411470
[TBL] [Abstract][Full Text] [Related]
14. Highly active antiretroviral therapy for injection drug users: physician-recommended strategies for enhanced adherence.
Vassilev ZP; Hagan H
Antivir Ther; 2004 Jun; 9(3):461. PubMed ID: 15259910
[No Abstract] [Full Text] [Related]
15. Take HAART: medication adherence in the era of highly active antiretroviral therapy.
Allardice K
Aust Nurs J; 2002 Apr; 9(9):19-21. PubMed ID: 12017049
[No Abstract] [Full Text] [Related]
16. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
[TBL] [Abstract][Full Text] [Related]
17. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.
Mehta SH; Lucas G; Astemborski J; Kirk GD; Vlahov D; Galai N
AIDS Care; 2007 May; 19(5):637-45. PubMed ID: 17505924
[TBL] [Abstract][Full Text] [Related]
18. A review of barriers and facilitators of HIV treatment among injection drug users.
Wood E; Kerr T; Tyndall MW; Montaner JS
AIDS; 2008 Jul; 22(11):1247-56. PubMed ID: 18580603
[TBL] [Abstract][Full Text] [Related]
19. Adherence to HAART among patients with HIV: breakthroughs and barriers.
Ickovics JR; Meade CS
AIDS Care; 2002 Jun; 14(3):309-18. PubMed ID: 12042076
[TBL] [Abstract][Full Text] [Related]
20. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004.
Donoghoe MC; Bollerup AR; Lazarus JV; Nielsen S; Matic S
Int J Drug Policy; 2007 Aug; 18(4):271-80. PubMed ID: 17689375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
